Greenwich Wealth Management LLC Sells 92 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 3rd, 2023

Greenwich Wealth Management LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,253 shares of the company’s stock after selling 92 shares during the quarter. Greenwich Wealth Management LLC’s holdings in Johnson & Johnson were worth $751,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Lincoln Capital Corp increased its position in shares of Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after buying an additional 183 shares during the period. Ieq Capital LLC increased its position in shares of Johnson & Johnson by 5.1% during the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after buying an additional 6,154 shares during the period. RFG Advisory LLC increased its position in shares of Johnson & Johnson by 2.7% during the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after buying an additional 594 shares during the period. Willis Investment Counsel increased its position in shares of Johnson & Johnson by 0.4% during the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after buying an additional 1,358 shares during the period. Finally, Wambolt & Associates LLC increased its position in shares of Johnson & Johnson by 2.5% during the fourth quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock worth $2,566,000 after buying an additional 355 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on JNJ. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 1st. StockNews.com began coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Atlantic Securities reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. Finally, UBS Group initiated coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Stock Up 0.9 %

JNJ opened at $165.03 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The company’s 50-day moving average is $158.00 and its 200 day moving average is $167.05. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The firm has a market capitalization of $429.79 billion, a P/E ratio of 34.53, a PEG ratio of 2.78 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The company had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. During the same period last year, the firm earned $2.67 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be given a $1.19 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.88%. Johnson & Johnson’s payout ratio is currently 94.56%.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.